smarter, simpler immunosuppressant monitoring: the promise of capillary blood microsampling innovation
For many organ transplant patients, immunosuppressant monitoring is a fact of life. But that does not mean that it cannot be significantly improved. For proof, look no further than the remote blood sampling capabilities provided by Mitra® microsampling devices, driven by Volumetric Absorptive Microsampling (VAMS®) technology.
Therapeutic Drug Monitoring for Transplant Recipients
Immunosuppressant regimens for patients who have received kidney transplants or other organ transplants require precise levels of drugs to be present in the bloodstream at all times. To ensure the treatment is working, these levels must be strictly monitored, requiring blood sampling at frequent and regular intervals.
Under old ways of blood collection, the inconvenience posed by therapeutic drug monitoring for organ transplant recipients is obvious. Patients must travel to clinics, sometimes at great distances, spending time away from home and family. This can impose constraints on lifestyle, along with a more general sense of frustration.
The Promise of Remote Sampling
New blood microsampling technology allows organ transplant recipients to collect samples anywhere, at any time, with minimal training - an innovation known as remote blood collection. From the perspective of patient experience, this makes immunosuppressant monitoring a lot more manageable.
Organ transplant recipients, at home - or wherever they want to be - can self-sample and ship. They can also claim greater agency and participation in their own treatment, making them feel more invested in its success.
The Science is Solid
But does blood microsampling produce samples that generate the same high-quality data associated with the gold standard of venous blood? Until recently, the answer was ambiguous.
Older dried blood collection methods, such as DBS cards, produced imprecise volumes of dried blood, leading to the hematocrit bias compromising data. Plus, they were cumbersome and unpleasant for patients, not much of an improvement over painful venipuncture with needles.
VAMS is different. Samples are volumetrically accurate. Self-sampling is considerably easier. And scientific results from third-party researchers prove that, with the right procedures in place, samples collected through microsampling generates results that correlate with those from plasma and venous blood.
Blood Microsampling in Tacrolimus Monitoring
There are still ample opportunities for researchers studying immunosuppressant monitoring for organ transplant patients to get involved with microsampling and join what is becoming a wave of success and validation.
This creates a model for how dried blood microsampling may expand to be applied to other immunosuppressant drugs and other analytes.
And what does that mean for patients?
New Possibilities for Organ Transplant Patients
Already, VAMS has enabled transplant patients to undertake a trek up Mt. Kilimanjaro, monitoring their immunosuppressant levels as they climbed. It has helped a pediatric kidney transplant patients stay closer to their families and communities.
And this is only the beginning. Like remote sampling itself, the biggest breakthroughs in using microsampling to monitor immunosuppressant drugs in transplant patients could happen anywhere. It could happen in your lab.
If you work with immunosuppressants, you need to understand VAMS. Contact us today, and one of our Microsampling Specialists will explore your unique situation and help you understand how to leverage the possibilities of this remarkable blood collection device.
Smarter, simpler sampling is the solution for better immunosuppressant monitoring. Start the conversation today!